Pfizer Inc. (PFE) Earnings

Management highlights

- CFO Transition Planning * Outgoing CFO Dave Denton will leave Pfizer for another opportunity, and has worked closely with incoming interim CFO Cécile Guégan to ensure a smooth transition. Guégan has deep experience shaping Pfizer's financial and strategic direction, and is fully prepared to take on the role. - Acquired Transaction Progress * Acquired product revenue grew 25% operationally year-over-year (excluding 2025 one-time items). The Seedzen acquisition expanded Pfizer's oncology ADC platform and pipeline, with legacy Seedzen portfolio revenue up 21% year-over-year in the U.S. (excluding 2025 one-time stocking benefits). The BioHeaven acquisition established Pfizer as a leader in migraine treatment; its lead product Nurtek continues to lead the oral CGRP class in total prescriptions and delivered strong year-over-year Q2 growth, with multiple expansion trials underway for new migraine indications. The Metera acquisition positions Pfizer in the large and growing obesity treatment market, with lead candidate verabenotide (a monthly GLP-1 receptor agonist) on track for a projected first approval in 2028. - R&D Pipeline Milestones * Through the first half of 2026, Pfizer achieved 3 regulatory approvals, 6 key data readouts, and 8 pivotal study starts. In the past two years, the oncology franchise has initiated 12 late-stage studies, delivered 21 late-stage data readouts, and earned 6 regulatory approvals. PADSEP received FDA label expansion to cover muscle invasive bladder cancer regardless of cisplatin eligibility, and a new bladder-sparing Phase 3 trial was initiated. Top pipeline candidates include metrometastat (an EZH2 inhibitor for prostate cancer, with a Phase 3 readout expected Q4 2026), Lidfulo for vitiligo (positive Phase 3 data readout this quarter), and 4404 (a PD-1/VEGF bispecific for non-small cell lung cancer with encouraging Phase 2 data). - Productivity and Cost Initiatives * Pfizer is expanding its cost improvement programs, now targeting $9.7 billion in total net cost savings through 2029, up from prior estimates. This includes $6.7 billion in net savings from the core productivity realignment program (an increase of $1 billion from prior guidance) and $3 billion in net savings from the multi-phase manufacturing optimization program (an increase of $1.5 billion from prior guidance). Additional savings will begin to be realized in 2027, supporting margin expansion and continued R&D investment. - AI Transformation * Management views AI as a structural transformation opportunity to accelerate R&D, improve business productivity, and strengthen competitive positioning. AI is already delivering benefits including reduced manufacturing costs, higher yields, and more effective commercial field execution and marketing. Pfizer's long-term goal is to build a fully AI-native R&D organization that leverages data continuously across all stages of drug discovery and development. - Capital Allocation Strategy * Pfizer maintains a disciplined capital allocation strategy focused on reinvesting in the business for growth, maintaining and over time growing the dividend, and retaining flexibility for future value-creating actions including share repurchases. In the first half of 2026, Pfizer invested $5.5 billion in internal and external R&D and returned $4.9 billion to shareholders via dividend. Leverage ended Q2 at 2.7x, and is expected to remain near current levels through the upcoming patent expiration (LOE) transition period.

Guidance

- Full year 2026 revenue guidance was raised, with the midpoint increased by $500 million to a new range of $60.5 billion to $62.5 billion, up from the prior range of 59.5 billion to $60.5 billion. The upward revision reflects stronger-than-expected performance across the non-COVID portfolio, which more than offset a $1 billion downward revision to projected 2026 COVID-19 revenues. - Adjusted diluted EPS guidance for full year 2026 is maintained at $2.80 to $3.00. The guidance range fully absorbs an approximate $0.10 unfavorable impact from the acquired in-process R&D charge related to the closed InnoVent Biologics transaction. - Pfizer reaffirms its long-term target of delivering risk-adjusted high single-digit revenue CAGR from the end of 2028 through the end of 2033, supported by the current in-line product base and 20 key pipeline candidates. The company remains on track to return to consistent growth from 2029 onward after the current LOE transition period. - Adjusted gross margin for full year 2026 is expected to land in the mid-70% range, in line with prior expectations.

Segment performance

Q2 2026 total revenue was $15 billion, representing a 1% year-over-year operational increase. Excluding COVID-19 products, the underlying business delivered 5% operational revenue growth. Adjusted diluted EPS was 77 cents, beating expectations, while reported GAAP loss per share was negative 4 cents. Launched and acquired products generated $3.2 billion in revenue with 18% operational growth in the quarter; excluding 2025 one-time items impacting the legacy C-Gen portfolio, acquired product growth hit 27%. Adjusted gross margin was 76%, driven by product mix and ongoing cost controls. Total adjusted operating expenses were $6.1 billion, a 4% operational increase year-over-year: adjusted SG&A decreased 3% operationally (driven by lower corporate enabling function spending), while adjusted R&D expenses increased 12% operationally (driven by higher spending on oncology and obesity candidates). Adjusted operating margin was 35%. COVID-19 revenue for full year 2026 is now projected at $4 billion, down from the prior projection of $5 billion, due to lower-than-expected infection rates.

Risks & headwinds

- Late-stage pipeline candidates are subject to technical, clinical, and regulatory risk that could prevent or delay approval, even after positive early-stage data. The recent Phase 3 SV readout in second-line plus non-small cell lung cancer did not meet the primary overall survival endpoint in the intention-to-treat population, leading to a $4.3 billion non-cash intangible asset impairment charge in Q2 2026, plus a downward revision to Xbrita revenue projections following discussions with the FDA. - COVID-19 revenue is highly dependent on infection rates, with antiviral Paxlovid revenue particularly correlated with seasonal infection fluctuations that are difficult to predict. Low COVID-19 infection rates in 2026 have already reduced projected full-year COVID-19 revenues by $1 billion, and continued low incidence could further limit tax credit utilization. - Upcoming patent expirations (LOEs) for multiple legacy products will create near-term revenue headwinds through the end of the decade, requiring Pfizer to offset these headwinds with growth from new and acquired products. - Proposed U.S. policy changes including the CMS 340B hospital reimbursement cut could negatively impact oncology portfolio revenue, though the final shape and outcome of the policy proposal remains uncertain as of the call.

Analyst Q&A

• Q: What defines success for the MEFRA-1 Phase 3 trial of metrometastat for prostate cancer, and is the trial fully enrolled?

  A: The trial is fully enrolled, but has not yet reached the required number of PFS events for readout, which is still expected in Q4 2026. Management views a 30% improvement over standard of care (a hazard ratio consistent with clinically meaningful benefit) as sufficient to validate the mechanism and support broad adoption. Early Phase 1 data showed a 49% reduction in progression risk, and competitor data has further supported the EZH2 inhibitor mechanism in this setting.

• Q: What is driving the upward revision to non-COVID revenue guidance, and what is the outlook for PADSEP growth after its recent label expansion?

  A: The upward guidance revision reflects broad-based strength across the non-COVID portfolio, including Eliquis, Nurtek, and PADSEP, not just a single product. Excluding 2025 one-time impacts, acquired products are growing 27% year-over-year, which contributed meaningfully to the upward revision. For PADSEP, indications now cover the full bladder cancer continuum, and Q2 growth exceeded 20% with new patient share now above 60%. Growth will moderate from its current rapid pace as it captures most eligible patients, but additional upside will come from the newly approved MIBC indication and the ongoing bladder-sparing trial.

• Q: What is the long-term commercial opportunity for metrometastat if the Phase 3 trial is successful?

  A: If approved, metrometastat can scale across the entire prostate cancer disease continuum, from early to late-stage settings. Unlike Xtandi, metrometastat will be 100% owned by Pfizer globally, so Pfizer will capture full value from the drug in both the U.S. and international markets, making it a potentially very large opportunity.

• Q: Would Pfizer ever consider cutting the dividend, given its BD investment needs?

  A: Management explicitly stated that even in the most challenging stretched scenarios the company models, Pfizer will be able to maintain the dividend. After the upcoming LOE transition period, the company expects to resume growing the dividend, and this is a core commitment to shareholders.

• Q: What is the long-term trajectory of COVID-19 revenue, and what are Pfizer's plans for its $6 billion remaining BD capacity?

  A: COVID-19 vaccine revenue will be relatively stable regardless of seasonal infection fluctuations, as vaccination is driven by perceived risk rather than current infection rates. Paxlovid revenue will remain highly correlated with annual infection rates, which vary unpredictably. Pfizer has already placed over $80 billion in large BD bets since 2022, with the three largest transactions (Seedzen, Metera, BioHeaven) all performing ahead of expectations. With remaining BD capacity, the company will pursue strategic bolt-on acquisitions in its core focus areas of oncology, immunology, obesity, and vaccines.